The combination of the drugs disitamab vedotin and toripalimab significantly prolongs the survival of patients with advanced urothelial cancer expressing HER2. Compared to chemotherapy, there was a 64% lower risk of disease progression and a 46% lower risk of death. Median overall survival was 31.5 months in the combination drug group versus 16.9 months in the chemotherapy group. The median time to disease progression was 13.1 months in the combination drug group and 6.5 months in the chemotherapy group. An objective response to treatment was observed in 76.1% of patients treated with a combination of drugs and in 50.2% of patients treated with chemotherapy. Grade ≥3 serious adverse events occurred in 55.1% of patients in the combination drug group and in 86.9% of patients in the chemotherapy group. The combination of disitamab vedotin and toripalimab represents a new treatment option for patients with HER2-expressing advanced urothelial cancer. The results are based on the phase III clinical trial RC48-C016.